Clinical trials: Stenosis, Aortic
Aortic Valve Stenosis
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
Prospective, multi-centre, multi-national registry with a follow-up of 3 months, in five European countries and Canada (Toronto), with elective patients undergoing TF-TAVI (n=120) and isolated SAVR (n=120), respectively and a…
- Trial name
- TASQ (NCT03186339)
- Testing
- TAVI, SAVR, MM
- Where
- 10 sites in Austria, Canada and 5 more
- Volunteers
- 272 people
- Sponsor
- Institut für Pharmakologie und Präventive Medizin
Hypertrophic Cardiomyopathy
A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's
The purpose of this study is to evaluate the AI-ECG algorithm for HCM in detecting HCM and in differentiating it from athlete's using not only the standard 12-lead ECG, but also ECGs obtained with the Apple Watch and Alivecor…
- Trial name
- NCT06290570
- Testing
- 12-Lead ECG, Apple Smart Watch Single Lead ECG, AliveCor KardiaMobile 6-Lead ECG
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Mayo Clinic
Aortic Valve Stenosis
Coronary and Structural Interventions - Transcatheter Aortic Valve Replacement
To evaluate the long-term results after transcatheter aortic valve replacement
- Trial name
- CSI-TAVR (NCT02162069)
- Testing
- CE certified transcatheter ( aortic valve replacement)
- Where
- Germany
- Volunteers
- 843 people
- Sponsor
- University of Ulm
Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR)
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Cardiac amyloidosis are related to the accumulation of fibrillar proteins in the extracellular leading to disruption of the cardiac tissue architecture.
- Conditions
- Cardiac Amyloidosis, Amyloidosis in Transthyretin (TTR), Hypertrophic Cardiomyopathy (HCM)
- Trial name
- Amylo (NCT01623245)
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Thibaud Damy
Hypertrophic Obstructive Cardiomyopathy (HOCM)
Clinical Outcomes of PIMSRA Treating for Hypertrophic Obstructive Cardiomyopathy: A Large-Sample Study
The Hypertrophic Cardiomyopathy Center of Xijing Hospital pioneered percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) as an innovative treatment for hypertrophic obstructive cardiomyopathy (HOCM) to relieve…
- Trial name
- NCT07003945
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Xijing Hospital
Hypertrophic Cardiomyopathy
Prospective Evaluation Of Exercise-Induced Cardiac Conduction Instability In Predicting Ventricular Fibrillation Events In Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is an inherited heart condition. Most people who have it are unaware of any problems relating to it.
- Trial name
- PREDICTVFII (NCT04157205)
- Testing
- Non-invasive ECG imaging - CardioInsight test
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Imperial College London
Aortic Valve Stenosis
VitaFlow LIBERTY Europe
This is a prospective, single-arm, multi-center, observational, post-market clinical investigation to document the clinical safety and performance of MicroPort CardioFlow VitaFlow Liberty™ Transcatheter Aortic Valve System in the…
- Trial name
- NCT06535659
- Testing
- VitaFlow Liberty™ Transcatheter Aortic Valve System
- Where
- 9 sites in Ireland, Italy and 3 more
- Volunteers
- 222 people
- Sponsor
- Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Apical Hypertrophic Cardiomyopathy
Surgical Treatment of the Patients With Restrictive Phenotype of the Hypertrophic Cardiomyopathy Without LVOT Obstruction
Hypertrophic cardiomyopathy - is an inherited disease characterized by pronounced genetic and phenotypic heterogeneity. There are two most common anatomic variants of cardiac hypertrophy: subaortic and submitral phenotypes.
- Trial name
- NCT06977646
- Testing
- Surgical transaortic left ventricular cavity remodeling in patients with apical hypertrophic cardiomyopathy without left ventricular outflow tract obstruction
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Obstructive Hypertrophic Cardiomyopathy
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea.
- Trial name
- NCT06146660
- Testing
- Mavacamten
- Where
- 2 sites in South Korea
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Glutathione Peroxidase Activity, Aortic Stenosis
GPx Activity in Subjects With Aortic Stenosis Undergoing TAVR
The aim of this project is to investigate the association of glutathione peroxidase (GPx) and severe aortic stenosis (AS), as well as the impact of transcatheter aortic valve replacement (TAVR) on GPx activity post-procedure.
- Conditions
- Glutathione Peroxidase Activity, Aortic Stenosis, Transcatheter Aortic Valve Replacement
- Trial name
- NCT04268160
- Testing
- Blood draw to measure GPx activity, Blood draw to measure SOD activity, Blood draw to measure Lp(a) levels
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Florida
Symptomatic Aortic Stenosis
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
The Keystone Heart TriGuard™ HDH is an aortic embolism deflection device intended to reduce the amount of embolic material that may enter the carotid, subclavian, and vertebral arteries during transcatheter heart valve…
- Trial name
- NCT02536196
- Testing
- Embolic Protection Device, Transcatheter aortic valve implantation (TAVI)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 478 people
- Sponsor
- Keystone Heart
Morality
Valvular Aortic Stenosis Prognosis Study
Aortic stenosis is the most common valvulopathy in Western countries. Cardiac EchoDoppler is the reference method for assessment of aortic stenosis and provides prognostic elements.
- Trial name
- EPRAoV (NCT03628313)
- Testing
- Transthoracic ultrasound
- Where
- France
- Volunteers
- 3,450 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Bicuspid Aortic Valve, Aortic Valve Stenosis
Progression of Ascending Aorta Diameters in Bicuspid Aortic Valve After Transcatheter or Surgical Replacement.
The goal of this prospective, non-randomized, single-center, observational study is to assess whether there is a progressive dilation of ascending aorta after surgical or transcatheter aortic valve replacement (TAVR) in patients…
- Conditions
- Bicuspid Aortic Valve, Aortic Valve Stenosis, Aortic Aneurysm, Heart Diseases
- Trial name
- ARDITAV (NCT05708118)
- Testing
- Echocardiographic assessment., Computed-tomography assessment
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiomyopathy, Hypertrophic Obstructive, Minimally Invasive Surgery
Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy
This single-center, prospective, open-label, randomized, controlled clinical trial is designed to assess the efficacy and safety of the Thoracoscopic Morrow procedure in the treatment of hypertrophic obstructive cardiomyopathy.
- Trial name
- NCT06391788
- Testing
- thoracoscopic Morrow surgery, modified Morrow surgery
- Where
- China
- Volunteers
- 132 people
- Sponsor
- China National Center for Cardiovascular Diseases
Transcatheter Aortic Valve Implantation
NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population
The study collects real-world data of patients who were treated with the ALLEGRA TAVI System TF and evaluates early and midterm clinical and quality of life outcome.
- Trial name
- FOLLOW (NCT03613246)
- Where
- 14 sites in Finland, Germany and 4 more
- Volunteers
- 346 people
- Sponsor
- NVT GmbH
Hypertrophic Obstructive Cardiomyopathy
Transapical Beating-Heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy: a Multi-Center Study
The primary purpose of this study is to evaluate the feasibility, the safety and the efficacy of the transapical beating-heart septal myectomy for the treatment of hypertrophic obstructive cardiomyopathy.
- Trial name
- NCT05957419
- Testing
- Transapical beating-heart septal myectomy
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Xiang Wei
Aortic Valve Disease, Aortic Valve Stenosis
Evaluating the Safety and Efficacy of Prosthetic Polymer Heart Valves for the Treatment of Aortic Valve Disease
The purpose of this study is to conduct the initial clinical investigation of the HeartHill Medical's polymer aortic valve, namely PoliaVavle，to collect evidence on the device's safety and performance.
- Conditions
- Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Regurgitation
- Trial name
- NCT06518681
- Testing
- PoliaValve (Aortic)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Suzhou Hearthill Medical Technology Co.,LTD
Aortic Stenosis
Prospective Balloon Aortic Valvuloplasty
The primary objective of this study is to determine the reasons for balloon aortic valvuloplasty (BAV) in the current clinical setting and to determine the outcomes of BAV in patients with aortic stenosis.
- Trial name
- BAV (NCT02122900)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Baylor Research Institute
Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation
Prospective Observational Cohort Study of Moderate Aortic Valve Disease
The objective of this research is to evaluate and predict the progression of moderate aortic stenosis and regurgitation from clinical characterization, biological, echocardiographic, and computed tomography (CT) et. al.
- Conditions
- Moderate Aortic Valve Stenosis, Moderate Aortic Valve Regurgitation, Aortic Valve Disease
- Trial name
- NCT06595992
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) >15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol
- Trial name
- TTRACK (NCT03842163)
- Testing
- Diagnosis of TTR amyloidosis cardiomyopathy
- Where
- 18 sites in Australia, Austria and 8 more
- Volunteers
- 812 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.